华东医药：控股子公司DR10624注射液获得美国FDA新药临床试验批准通知

Core Viewpoint - The announcement highlights that Zhejiang Daer Biotechnology, a subsidiary of Huadong Medicine, has received FDA approval for the clinical trial application of the drug DR10624, aimed at treating Metabolic Associated Steatotic Liver Disease (MASLD) [1] Group 1 - The drug DR10624 is a globally innovative long-acting tri-specific agonist targeting FGF21R, GCGR, and GLP-1R, developed independently by Daer Biotechnology [1] - DR10624 has successfully completed Phase II clinical trials for severe hypertriglyceridemia, achieving positive top-line results [1] - The approval for the clinical trial will not have a significant impact on the company's recent performance [1]